Background Leukemia is a type of cancer that affects the blood and bone marrow. This paper highlights the role of nicotinamide adenine din- ucleotide (NAD) consuming enzymes such as CD38, PARP1, and SIRT1 in patients with acute lymphocytic leukemia, acute myeloid leukemia, and patients suffering from chronic myeloid leukemia.
Materials and methods Based on recent data. 40 patients with acute lymphocytic leukemia (ALL), 40 patients with acute myeloid leukemia (AML), 30 patients with chronic myeloid leukemia (CML), and 40 healthy persons served as controls. The enzyme-linked immunosorbent assay (ELISA) sandwich technique was used to detect the serum levels of CD38, PARP1, and SIRT1.
Results In patient, groups compared to the control group, CD38 con- centrations were discovered to be considerably higher (p < 0.05), especially in the CML group, also Comparing patient groups to the control group, it was discovered that the amounts of PARP1 were considerably greater (p < 0.05), especially CML group, and When compared to the control group, the patient groups’ SIRT1 concentrations were discovered to be considerably greater, especially AML group (p < 0.05).
Conclusion The results obtained show that there is a reliable correla- tion between the NAD-dependent enzymes and groups of patients suffering from leukemia and are considered predictive indicators of the pathological condition that can be used in the future in treatments.